Survival prediction by Bayesian network modeling for pseudomyxoma peritonei after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy

被引:5
作者
Zhao, Xin [1 ]
Li, Xinbao [2 ]
Lin, Yulin [2 ]
Ma, Ru [2 ]
Zhang, Ying [2 ]
Xu, Dazhao [2 ]
Li, Yan [1 ,2 ]
机构
[1] Peking Univ, Sch Clin Med 9, Dept Peritoneal Canc Surg, Beijing Shijitan Hosp, 10 Tieyi Rd,Yangfangdian St, Beijing 100038, Peoples R China
[2] Capital Med Univ, Beijing Shijitan Hosp, Dept Peritoneal Canc Surg, Beijing, Peoples R China
来源
CANCER MEDICINE | 2023年 / 12卷 / 03期
关键词
Bayesian network; cytoreductive surgery; hyperthermic intraperitoneal chemotherapy; pseudomyxoma peritonei; survival prognostic model; NEOPLASMS; OUTCOMES;
D O I
10.1002/cam4.5138
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives To establish a survival prognostic model for pseudomyxoma peritonei (PMP) treated with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) based on Bayesian network (BN). Methods 453 PMP patients were included from the database at our center. The dataset was divided into a training set to establish BN model and a testing set to perform internal validation at a ratio of 8:2. From the training set, univariate and multivariate analyses were performed to identify independent prognostic factors for BN model construction. The confusion matrix, receiver operating characteristic (ROC) curve and the area under curve (AUC) were used to evaluate the performance of the BN model. Results The univariate and multivariate analyses identified 7 independent prognostic factors: gender, previous operation history, histological grading, lymphatic metastasis, peritoneal cancer index, completeness of cytoreduction and splenectomy (all p < 0.05). Based on independent factors, the BN model of training set was established. After internal validation, the accuracy and AUC of the BN model were 70.3% and 73.5%, respectively. Conclusion The BN model provides a reasonable level of predictive performance for PMP patients undergoing CRS + HIPEC.
引用
收藏
页码:2637 / 2645
页数:9
相关论文
共 50 条
  • [41] Drug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma Peritonei
    Kathrine Bjersand
    Haile Mahteme
    Inger Sundström Poromaa
    Håkan Andréasson
    Wilhelm Graf
    Rolf Larsson
    Peter Nygren
    Annals of Surgical Oncology, 2015, 22 : 810 - 816
  • [42] Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for Pseudomyxoma peritonei originating from ovarian teratomas: A single-center case series and literature review
    Shi, Guanjun
    Wang, Chong
    Lu, Yiyan
    Zhang, Pu
    An, Lubiao
    Zhou, Haipeng
    Ma, Ruiqing
    Shou, Huafeng
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2025, 309 : 107 - 112
  • [43] Prospective longitudinal study of quality of life following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei
    Alves, S.
    Mohamed, F.
    Yadegarfar, G.
    Youssef, H.
    Moran, B. J.
    EJSO, 2010, 36 (12): : 1156 - 1161
  • [44] Critical Assessment of Risk Factors for Complications After Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei
    Akshat Saxena
    Tristan D. Yan
    Terence C. Chua
    David L. Morris
    Annals of Surgical Oncology, 2010, 17 : 1291 - 1301
  • [45] Overall survival of pseudomyxoma peritonei and peritoneal mesothelioma patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy can be predicted by computed tomography quantified sarcopenia
    Galan, Alexandre
    Rousset, Pascal
    Mercier, Frederic
    Kepenekian, Vahan
    Valette, Pierre-Jean
    Glehen, Olivier
    Passot, Guillaume
    EJSO, 2018, 44 (11): : 1818 - 1823
  • [46] Cellularity in low-grade Pseudomyxoma peritonei impacts recurrence-free survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Horvath, Philipp
    Yurttas, Can
    Birk, Philipp
    Struller, Florian
    Koenigsrainer, Alfred
    LANGENBECKS ARCHIVES OF SURGERY, 2018, 403 (08) : 985 - 990
  • [47] Cellularity in low-grade Pseudomyxoma peritonei impacts recurrence-free survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Philipp Horvath
    Can Yurttas
    Philipp Birk
    Florian Struller
    Alfred Königsrainer
    Langenbeck's Archives of Surgery, 2018, 403 : 985 - 990
  • [48] Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Blackham, Aaron U.
    Swett, Katrina
    Eng, Cathy
    Sirintrapun, Joseph
    Bergman, Simon
    Geisinger, Kim R.
    Votanopoulos, Konstantinos
    Stewart, John H.
    Shen, Perry
    Levine, Edward A.
    JOURNAL OF SURGICAL ONCOLOGY, 2014, 109 (07) : 740 - 745
  • [49] Long-term outcomes and survival analysis of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei at a newly established peritoneal malignancy centre in Japan
    Yano, Hideaki
    Gohda, Yoshimasa
    Moran, Brendan J.
    Suda, Ryuichiro
    Kokudo, Norihiro
    ANNALS OF GASTROENTEROLOGICAL SURGERY, 2024, 8 (04): : 701 - 710
  • [50] Successful treatment of pseudomyxoma peritonei (PMP) through cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC): A case report and literature review
    Awad, Areej
    Awad, Mahmoud
    Alami, Muayyad
    Abu Sablan, Aseel
    Shrateh, Oadi N.
    Jubran, Fahmi
    INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS, 2024, 119